Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein

Thrombosis and Haemostasis

Volumn 90, Issue 1, 2003, Pages 124-131

  Lacut, Karine ^a   Oger, Emmanuel ^a   Le Gal, Grégoire ^a   Blouch, Marie Thérèse ^a   Abgrall, Jean François ^a   Kerlan, Véronique ^a   Scarabin, Pierre Yves ^b   Mottier, Dominique ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b INSERM   (France)

Author keywords

C reactive protein; Inflammation; Interleukine 6; Oral estrogen replacement therapy; Randomised trial; Transdermal estrogen replacement therapy; Tumor necrosis factor alpha

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PLACEBO; PROGESTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DYSLIPIDEMIA; EDEMA; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; SMOKING; SYSTOLIC BLOOD PRESSURE; TRANSDERMAL PATCH; VAGINA BLEEDING;

EID: 0037695801     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613608     Document Type: Article

References (40)

1. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 115-26
2. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111: 98-111
3. Carson SD, Johnson DR. Consecutive enzyme cascades: Complement activation at the cell surface triggers increased tissue factor activity. Blood 1990; 762:361-7
4. Hamilton KK, Hattori R, Esmon CT, et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for the assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-14
5. Hugo F, Hamdoch T, Mathey D, et al. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol 1990; 81: 132-6
6. Mathey D, Schofer J, Schäfer HJ, et al. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 1994; 15: 418-23
7. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9
8. Koenig W, Sund M, Frölich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 - 1992. Circulation 1999; 99: 237-42
9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
10. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-47
11. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-6
12. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation 1999; 100: 1148-50
13. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72
14. Ridker PM, Rifai N, Pfeffer M, et al. For the Cholesterol And Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53
15. Lowe GDO, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein. Thromb Haemost 2001; 86: 550-6
16. Van Baal WM, Kenemans P, Van der Mooren MJ, et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-8
17. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Post-menopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-22
18. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
19. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893-9
20. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002; 105: 1436-9
21. Hulley S, Grady D, Bush T, et al. for the HERS Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13
22. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from Women's Health Initiative randomised controlled trial. JAMA 2002; 288: 321-33
23. Post MS, Van Der Mooren MJ, Stehouwer CDA, et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: A randomised, placebo-controlled trial. Thromb Haemost 2002; 88: 605-10
24. Oger E, Alhenc-Gelas M, Plu-Bureau G, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001; 101: 35-43
25. Sattar N, Perera M, Small M, et al. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 1999; 354: 487-8
26. Howard BV, Magee MF. Diabetes and cardiovascular disease. Curr Atheroscler Rep 2000; 2: 476-81
27. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25
28. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomised, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-8
29. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002; 109: 1056-62
30. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17β in postmenopausal women: Oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-41
31. Van Baal WM, Kooistra T, Stehouver DA. Cardiovascular disease risk and hormone replacement therapy (HRT): A review based on randomised, controlled studies in postmenopausal women. Curr Med Chem 2000; 7: 499-517
32. Van Snik J. Interleukin-6: An overview. Annu Rev Immunol 1993; 8: 253-78
33. Ng SB, Tan YN, Guy GR Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 1994; 269: 19021-7
34. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36
35. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med. 1990; 7: 147-159
36. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-86
37. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-12
38. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86: 4216-22
39. Walsh BW, Cox DA, Sashegyi A, et al. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88: 825-8
40. Kon Koh K, Schenke WH, Waclawiw MA, et al. Cannon RO 3rd. Stain attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002; 105: 1531-3